Pharmaceutical Insights
Navigate pharmaceutical trends with our insights on targets, institutional pipelines, clinical advances, and new drugs.
blog-list-cover
Recent blog posts
IASO-782 in Systemic Lupus Erythematosus: NCT07483346 Clinical Landscape Report 2026
9 min read
IASO-782 in Systemic Lupus Erythematosus: NCT07483346 Clinical Landscape Report 2026
18 September 2026
NCT07483346 clinical landscape for Systemic Lupus Erythematosus: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Ocrelizumab in Multiple Sclerosis, Primary Progressive: NCT07483450 Clinical Landscape Report 2026
9 min read
Ocrelizumab in Multiple Sclerosis, Primary Progressive: NCT07483450 Clinical Landscape Report 2026
18 September 2026
NCT07483450 clinical landscape for Multiple Sclerosis, Primary Progressive: endpoints, sponsor, phase, geography, readouts, asset context and development whi…
Read →
JL-19001 in Non-Muscle Invasive Bladder Neoplasms: NCT07483970 Clinical Landscape Report 2026
9 min read
JL-19001 in Non-Muscle Invasive Bladder Neoplasms: NCT07483970 Clinical Landscape Report 2026
18 September 2026
NCT07483970 clinical landscape for Non-Muscle Invasive Bladder Neoplasms: endpoints, sponsor, phase, geography, readouts, asset context and development white…
Read →
Venetoclax in Relapsing acute myeloid leukemia: NCT07486726 Clinical Landscape Report 2026
9 min read
Venetoclax in Relapsing acute myeloid leukemia: NCT07486726 Clinical Landscape Report 2026
18 September 2026
NCT07486726 clinical landscape for Relapsing acute myeloid leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white spac…
Read →
Olutasidenib in Acute Myeloid Leukemia: NCT07486713 Clinical Landscape Report 2026
9 min read
Olutasidenib in Acute Myeloid Leukemia: NCT07486713 Clinical Landscape Report 2026
18 September 2026
NCT07486713 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
HBM7575 in Dermatitis, Atopic: NCT07488065 Clinical Landscape Report 2026
9 min read
HBM7575 in Dermatitis, Atopic: NCT07488065 Clinical Landscape Report 2026
18 September 2026
NCT07488065 clinical landscape for Dermatitis, Atopic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Adalimumab in Arthritis, Psoriatic: NCT07486843 Clinical Landscape Report 2026
9 min read
Adalimumab in Arthritis, Psoriatic: NCT07486843 Clinical Landscape Report 2026
18 September 2026
NCT07486843 clinical landscape for Arthritis, Psoriatic: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Metformin Hydrochloride in Plaque psoriasis: NCT07485764 Clinical Landscape Report 2026
9 min read
Metformin Hydrochloride in Plaque psoriasis: NCT07485764 Clinical Landscape Report 2026
18 September 2026
NCT07485764 clinical landscape for Plaque psoriasis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
CD19/BCMA-targeted CAR-T lentiviral vector drug(Shenzhen Genocury Biotech) in Sjogren's Syndrome: NCT07490951 Clinical Landscape Report 2026
9 min read
CD19/BCMA-targeted CAR-T lentiviral vector drug(Shenzhen Genocury Biotech) in Sjogren's Syndrome: NCT07490951 Clinical Landscape Report 2026
18 September 2026
NCT07490951 clinical landscape for Sjogren's Syndrome: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
SHR-3836 in Multiple Myeloma: NCT07490613 Clinical Landscape Report 2026
9 min read
SHR-3836 in Multiple Myeloma: NCT07490613 Clinical Landscape Report 2026
18 September 2026
NCT07490613 clinical landscape for Multiple Myeloma: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Venetoclax in Acute Myeloid Leukemia: NCT07490288 Clinical Landscape Report 2026
9 min read
Venetoclax in Acute Myeloid Leukemia: NCT07490288 Clinical Landscape Report 2026
18 September 2026
NCT07490288 clinical landscape for Acute Myeloid Leukemia: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →
Fludarabine Phosphate in Myositis: NCT07490275 Clinical Landscape Report 2026
9 min read
Fludarabine Phosphate in Myositis: NCT07490275 Clinical Landscape Report 2026
18 September 2026
NCT07490275 clinical landscape for Myositis: endpoints, sponsor, phase, geography, readouts, asset context and development white space.
Read →